MEDIAN Technologies Unveils a Unique Product for Oncology Clinical Trials: CTIS

SOPHIA ANTIPOLIS, NICE, France--(BUSINESS WIRE)-- Regulatory News:

CTIS integrates MEDIAN’s LMS solutions into a collaborative workflow among the various stakeholders involved in clinical trials in order

to optimise utilization of images and enhance reliability of results.

MEDIAN Technologies (Paris: ALMDT)(ALMDT), the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, announced the introduction on the market of its CTIS product - Clinical Trial Imaging Services.

Today,

  • discordance among the various image readers (24 to 39 % of cases*),
  • loss of patients due to missing images (11 to 13 % of cases*),
  • enrollment of patients without measurable diseases (up to 9 % of cases*), reduce the quality and the reliability of clinical trial results, negatively impacting on Go/NoGo decisions, trial duration, and cost.

*European Journal of Cancer 45 (2009) 268-274

Taking this into account, CTIS is a package of innovative services that optimises the use of medical images in oncology clinical trials. CTIS is targeted to the various stakeholders involved in trials including investigator sites, independent reviewers and sponsors. CTIS provides concrete solutions to frequently-observed imaging problems in oncology clinical trials: variability in image interpretation, censoring bias, difficult implementation of advanced imaging biomarkers, complex workflows and management of image databases.

MEDIAN Technologies CEO Frederik Brag commented that « With CTIS, we have developed an innovative solution for the end-to-end management of oncology clinical trials. This solution is well adapted to the problems encountered by pharmaceutical companies in the context of these clinical trials and has already been adopted by three of the biggest pharmaceutical companies worldwide.”

The CTIS package includes four kinds of services that can be customized per trials:

1. Management of investigator sites : site qualification, site training, implementation of infrastructure for onsite image reading, onsite quality control, optimization of imaging data workflow,

2. Independent review services, double reading and adjudication,

3. Centralized databases and on-demand functionalities, sponsor access : project dashboards, data mining, access to all images and data via MEDIAN LMS

4. Advanced reviewing services providing advanced imaging biomarkers.

The CTIS package is based on MEDIAN Technologies LMS (Lesion Management Solutions) that can be used on investigator sites, independent review sites and sponsor sites.

Lesion Management Solutions (LMS) detect, evaluate and follow-up automatically lesions identified in computed tomography (CT) scans. LMS provide response criteria that are utilized for the evaluation of patient response to therapy (such as lesion diameter); they also perform automated measurements of advanced lesion parameters (such as volume, density…), thus allowing the implementation of advanced imaging biomarkers. LMS automation capabilities result in image reading standardization and interpretation variability decrease.

Lesion Management Solutions are compatible with all types of CT scanner. They can be integrated into heterogeneous IT environments and easily deployed at sites with very diverse equipment and software configurations.

The MEDIAN Technologies LMS are "software as a service" (SaaS) products; they are web-based, fully distributed and available anywhere in the world. They are therefore available without any geographic constraints; this represents a key advantage for multicentric clinical trials.

About MEDIAN Technologies

MEDIAN Technologies was founded in 2002 by Fredrik Brag (the current Chairman and CEO), Gérard Milhiet and Arnaud Butzbach. It is based at Sophia Antipolis (in the south of France) and has a subsidiary in the USA. The company currently has a staff of 40, over half of whom work in R&D.

MEDIAN Technologies offers solutions and services for diagnosing and monitoring cancer patients. It is targeting both the oncology clinical trials market (its prime market) and the patient care market.

MEDIAN Technologies collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), Chicago University and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN Technologies has been present in the market since 2007 through direct sales of its lesion management solutions and alliances with specialist cancer centers in Europe and the USA.

For more information about MEDIAN, visit www.mediantechnologies.com.

Biomarkers in medical imaging are the key to detecting and treating cancer



CONTACT:

MEDIAN Technologies
Fredrik Brag, CEO
+33 492 906 582
[email protected]
or
ALIZE RP
Caroline Carmagnol
+ 33 664 189 959
[email protected]

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.